The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View

Author(s): D. O. Stichtenoth

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 4 , Issue 6 , 2004


Become EABM
Become Reviewer
Call for Editor

Abstract:

Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. In comparison to the first generation, they show an at least equivalent efficacy in the treatment of pain and inflammation. However, the postulated gain of safety is yet difficult to determine and seems to be, if any, small.

Keywords: safety, efficacy, pain, inflammation, valdecoxib, parecoxib, etoricoxib, lumiracoxib

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 6
Year: 2004
Published on: 01 March, 2012
Page: [617 - 624]
Pages: 8
DOI: 10.2174/1389557043403783
Price: $65

Article Metrics

PDF: 9